H
Hans-Peter Lenhof
Researcher at Saarland University
Publications - 170
Citations - 6982
Hans-Peter Lenhof is an academic researcher from Saarland University. The author has contributed to research in topics: Cancer & Macromolecular docking. The author has an hindex of 44, co-authored 164 publications receiving 6046 citations. Previous affiliations of Hans-Peter Lenhof include Max Planck Society.
Papers
More filters
Journal ArticleDOI
Is there a general autoantibody signature for cancer
Nicole Ludwig,Andreas Keller,Petra Leidinger,Christian Harz,Christina Backes,Hans-Peter Lenhof,Eckart Meese +6 more
TL;DR: It is shown that proteins that are frequently reactive with cancer sera are alsorequently reactive with non-cancer sera, which underline the potential of autoantibody signatures for cancer diagnosis and caution to premature claim specificity of a signature.
Journal ArticleDOI
Genetic alterations of the SUMO isopeptidase SENP6 drive lymphomagenesis and genetic instability in diffuse large B-cell lymphoma
Markus Schick,Le Zhang,Sabine Maurer,H. Carlo Maurer,Konstandina Isaakaidis,Lara Schneider,Upayan Patra,Kathrin Schunck,Elena Rohleder,Julia-Silvana Hofstetter,Apoorva Baluapuri,Anna Katharina Scherger,Julia Slotta-Huspenina,F. Hettler,Julia Weber,Thomas Engleitner,Roman Maresch,Jolanta Slawska,Richard Lewis,Rouzanna Istvanffy,Stefan Habringer,Katja Steiger,Armin Baiker,Robert A.J. Oostendorp,Cornelius Miething,Hans-Peter Lenhof,Florian Bassermann,Björn Chapuy,Matthias Wirth,Elmar Wolf,Roland Rad,Stefan Müller,Ulrich auf dem Keller +32 more
TL;DR: In this paper , the authors identified the SUMO isopeptidase (or deconjugase) SENP6 as a tumor suppressor that links unrestricted SUMOylation to tumor development and progression and revealed the potential therapeutic application of PARP inhibitors in B-cell lymphoma.
Journal ArticleDOI
ClinOmicsTrailbc: a visual analytics tool for breast cancer treatment stratification.
Lara Schneider,Tim Kehl,Kristina Thedinga,Nadja Grammes,Christina Backes,Christopher Mohr,Benjamin Schubert,Kerstin Lenhof,Nico Gerstner,Andreas D. Hartkopf,Markus Wallwiener,Oliver Kohlbacher,Andreas Keller,Eckart Meese,Norbert Graf,Hans-Peter Lenhof +15 more
TL;DR: ClinOmicsTrailbc is a powerful integrated visual analytics tool for breast cancer research in general and for therapy stratification in particular, assisting oncologists to find the best possible treatment options for their breast cancer patients based on actionable, evidence-based results.
Journal ArticleDOI
Quantitative and time-resolved miRNA pattern of early human T cell activation
Caroline Diener,Martin Hart,Tim Kehl,Stefanie Rheinheimer,Nicole Ludwig,Lena Krammes,Sarah Pawusch,Kerstin Lenhof,Tanja Tänzer,David Schub,Martina Sester,Barbara Walch-Rückheim,Andreas Keller,Andreas Keller,Hans-Peter Lenhof,Eckart Meese +15 more
TL;DR: A quantitative and time-resolved expression pattern for the entire miRNome over a period of 24 h upon human T-cell activation is established and comprehensive insights into the range of stimulus induced miRNA abundance changes are provided.
Journal ArticleDOI
Genetic alterations of the SUMO isopeptidase SENP6 drive lymphomagenesis and genetic instability in diffuse large B-cell lymphoma
Markus Schick,Le Zhang,Sabine Maurer,H. Carlo Maurer,Konstandina Isaakaidis,Lara Schneider,Upayan Patra,Kathrin Schunck,Elena Rohleder,Julia-Silvana Hofstetter,Apoorva Baluapuri,Anna Katharina Scherger,Julia Slotta-Huspenina,F. Hettler,Julia Weber,Thomas Engleitner,Roman Maresch,Jolanta Slawska,Richard Lewis,Rouzanna Istvanffy,Stefan Habringer,Katja Steiger,Armin Baiker,Robert A.J. Oostendorp,Cornelius Miething,Hans-Peter Lenhof,Florian Bassermann,Björn Chapuy,Matthias Wirth,Elmar Wolf,Roland Rad,Stefan Müller,U. Keller +32 more
TL;DR: In this paper , the authors identified the SUMO isopeptidase (or deconjugase) SENP6 as a tumor suppressor that links unrestricted SUMOylation to tumor development and progression and revealed the potential therapeutic application of PARP inhibitors in B-cell lymphoma.